Allergan cleared by FDA for Juvéderm VOLUMA XC for mid-face injection via cannulaSeptember 3, 2019
Allergan got U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.
A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm VOLUMA XC in the cheek area. The TSK STERiGLIDE™ has a unique design compared to other cannulas available on the market and features a patented tip design with a near-tip delivery port for precise product placement, Allergan said in the press release Tuesday.
Dr. Dee Anna Glaser, a board-certified dermatologist in St. Louis and clinical trial investigator, said: “As a physician, I have used the Juvéderm Collection of Fillers for 13 years, so I am thrilled that the FDAhas approved the use of cannula with Juvéderm VOLUMA XC for mid-face volume deficit. With this latest approval, I have another effective option to provide volume and contour in the mid-face area. I can tailor my treatment approach for each patient while safely providing the aesthetic outcomes they wish to achieve.”
Carrie Strom, Senior Vice President of U.S. Allergan Medical Aesthetics, said: “With this approval, Allergan will be able to educate on facial anatomy and injection techniques that will help healthcare providers administer treatment with Juvéderm VOLUMA® XC safely to achieve optimal patient satisfaction.”